To date, numerous preliminary and multicenter clinical studies have confirmed that the OSNA assay can be applied to evaluate LNM in various cancers expressing CK19, such as breast cancer, cervical and endometrial cancer, lung cancer, gastric cancer, and colorectal cancer (8, 11–13). The gene discussed is KRT19; the disease is breast carcinoma.